The Alaska House Labor and Commerce Committee voted Tuesday to advance a bill requiring insurance coverage for pediatric autoimmune neuropsychiatric disorders after parents testified their children experienced hallucinations, suicidal thoughts, and lasting harm from delayed treatment.

The committee passed House Bill 292 in just two hearings after hearing from families who paid tens of thousands of dollars out of pocket when insurers denied coverage for treatments including intravenous immunoglobulin therapy.

Representative Carolyn Hall moved to report the bill from committee with individual recommendations and accompanying fiscal notes. The bill passed without objection.

The legislation requires private insurers to cover evaluation and specified treatments for PANDAS and PANS, conditions triggered by infections that cause sudden onset of obsessive-compulsive disorder, tics, anxiety, and other neuropsychiatric symptoms in children.

Before the vote, the committee adopted two technical amendments. The first replaced language referencing a medical consortium with a requirement that coverage follow "nationally recognized clinical practice guidelines." Evan Anderson, staff to Representative Fields assisting with Representative Kahlom's office, said the guidelines establish standards of care informed by systematic review of evidence and assessment of benefits and risks of alternative care options.

The second amendment changed "health benefit plan" to "healthcare insurance plan" to align with other insurance mandate statutes.

Parents who testified described children whose symptoms escalated rapidly without treatment. One mother said her daughter developed dangerous hallucinations and expressed thoughts of self-harm just two months after symptom onset. Another said her son, now 21, has suffered for nine years and was repeatedly told his symptoms were "all in his head" before receiving a correct diagnosis.

Adam Ebnet, a South Anchorage resident, said his family traveled to Minnesota for treatment after Alaska providers could not help their three-year-old son. The family paid more than $20,000 out of pocket after their insurance company refused to cover any portion of the bills.

"We are very hopeful that insurance would cover some or all of them, but they were not interested in paying anything or entertaining paying a portion of any of the bills for his treatment for the PANDAS," Ebnet said.

Several parents emphasized that delays in treatment caused permanent deficits their children might not have experienced with earlier access to care. One mother said the three-month delay her family faced in getting insurance approval may have contributed to lasting impairments her daughter now experiences at age 16.